20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Enliven Therapeutics Inc. (ELVN) operates in the BIOTECHNOLOGY industry and is headquartered in Boulder, United States with about 67 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, ELVN reported $0M in revenue and ($104M) in net income.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — | — | — |
| Gross Profit | — | $0M | $0M | $0M | ($1M) | $0M | $0M | $0M | — | — |
| Gross Margin % | — | — | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($124M) | ($120M) | ($105M) | ($84M) | ($39M) | ($25M) | ($9M) | ($24M) | ($11M) | ($9M) |
| Operating Margin % | — | — | — | — | — | — | — | — | — | — |
| Net Income | ($106M) | ($104M) | ($89M) | ($72M) | ($38M) | ($25M) | ($19M) | ($23M) | ($11M) | — |
| Net Margin % | — | — | — | — | — | — | — | — | — | — |
| EBITDA | ($106M) | ($103M) | ($88M) | ($71M) | ($37M) | ($25M) | ($9M) | ($23M) | ($11M) | $0M |
| Earnings Per Share (EPS) | $-1.72 | $-1.83 | $-1.89 | $-2.01 | $-6.03 | $-3.17 | $-4.32 | $-5.43 | $-2.62 | — |
| Shares Outstanding (M) | 66M | 57M | 47M | — | 6M | 8M | 4M | 4M | 4M | 4M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | — | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | 50.0% | — |
| Operating Income (EBIT) | ($37M) | ($28M) | ($34M) | ($25M) | ($29M) | ($32M) | ($27M) | ($27M) |
| Operating Margin % | — | — | — | — | — | — | -8511.4% | — |
| Net Income | ($32M) | ($24M) | ($30M) | ($20M) | ($25M) | ($29M) | ($23M) | ($23M) |
| Net Margin % | — | — | — | — | — | — | -7335.4% | — |
| EBITDA | ($32M) | ($24M) | ($30M) | ($20M) | ($25M) | ($28M) | ($23M) | ($23M) |
| Earnings Per Share (EPS) | $-0.49 | $-0.38 | $-0.52 | $-0.32 | $-0.49 | $-0.57 | $-0.46 | $-0.48 |
| Shares Outstanding (M) | 66M | 63M | 57M | 62M | 52M | 50M | 50M | 48M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($67M) | ($70M) | ($73M) | ($61M) | ($32M) | ($19M) | ($9M) | ($22M) | ($9M) | ($9M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $1M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($67M) | ($70M) | ($73M) | ($61M) | ($33M) | ($19M) | ($9M) | ($22M) | ($9M) | ($9M) |
| FCF Margin % | — | — | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($19M) | ($19M) | ($16M) | ($13M) | ($17M) | ($24M) | ($17M) | ($12M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($19M) | ($19M) | ($16M) | ($13M) | ($17M) | ($24M) | ($17M) | ($12M) |
| FCF Margin % | — | — | — | — | — | — | -5444.0% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $910M | $476M | $326M | $272M | $83M | $113M | $91M | $33M | $8M | $10M |
| Cash & Cash Equivalents | $136M | $99M | $124M | $100M | $76M | $110M | $48M | $5M | $7M | $10M |
| Total Liabilities | $15M | $17M | $16M | $26M | $160M | $6M | $6M | $4M | $2M | $1M |
| Total Debt (Short + Long-Term) | $1M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $895M | $460M | $310M | $246M | ($77M) | $107M | $84M | ($49M) | ($26M) | ($16M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ELVN viewer.
About TickerBase · Data methodology & sources · Privacy · Terms